| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 02/17/2005 | CA2534659A1 A variant cell surface molecule associated with cancer |
| 02/17/2005 | CA2534658A1 Trefoil factor 3 (tff3) as a target for anti-cancer therapy |
| 02/17/2005 | CA2533550A1 Antigen delivery system |
| 02/17/2005 | CA2533540A1 Targeted therapeutic vaccine against p-glycoprotein 170 for inhibiting multi-drug resistance in the treatment of cancers |
| 02/17/2005 | CA2532759A1 Active or passive immunization against proapoptotic neurotrophins for the treatment and/or prevention of neurodegenerative diseases |
| 02/17/2005 | CA2532721A1 Ra antigenic peptides |
| 02/17/2005 | CA2532140A1 Vaccines using pattern recognition receptor-ligand:lipid complexes |
| 02/17/2005 | CA2531032A1 Programmed immune responses using a vaccination node |
| 02/17/2005 | CA2529623A1 Antibodies specific for sclerostin and methods for increasing bone mineralization |
| 02/17/2005 | CA2528606A1 Gene expression profiling in primary ovarian serous papillary tumors and normal ovarian epithelium |
| 02/17/2005 | CA2526900A1 Truncated fragments of alpha-synuclein in lewy body disease |
| 02/17/2005 | CA2526274A1 Prostate stem cell antigen (psca) variants and subsequences thereof |
| 02/17/2005 | CA2523676A1 Dna vaccine expressing ha1 of equine-2 influenza virus |
| 02/17/2005 | CA2519294A1 Newcastle disease virus administration |
| 02/17/2005 | CA2517181A1 Methods of producing influenza vaccine compositions |
| 02/17/2005 | CA2501889A1 Use of beta-glucans against biological warfare weapons and pathogens including anthrax |
| 02/16/2005 | EP1507007A1 Cell cycle related proteins |
| 02/16/2005 | EP1506787A1 Vascular endothelial cell growth factor antagonists |
| 02/16/2005 | EP1506301A1 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome |
| 02/16/2005 | EP1506297A2 Brachyspira hyodysenteriae vaccine |
| 02/16/2005 | EP1506295A2 Muteins of placental growth factor type 1, preparation method and application thereof |
| 02/16/2005 | EP1506286A2 Neutralizing human anti-igfr antibody |
| 02/16/2005 | EP1506285A2 Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents |
| 02/16/2005 | EP1506237A1 Treatment of cancer by the use of anti fas antibody |
| 02/16/2005 | EP1506225A2 Novel peptide compositions and the use thereof, in particular, in the preparation of active pharmaceutical compositions against the hepatitis c virus |
| 02/16/2005 | EP1506224A1 Polypeptide antigen inducing hiv neutralizing antibodies |
| 02/16/2005 | EP1506223A1 Fusion protein of hiv regulatory/accessory proteins |
| 02/16/2005 | EP1506215A2 Novel polypeptides having sequence similarity to gdnfr and nucleic acids encoding the same |
| 02/16/2005 | EP1506019A1 Complexes for the delivery of biologically-active material to cells |
| 02/16/2005 | EP1506013A1 Chimeric allograft tolerance induction, monitoring and maintenance |
| 02/16/2005 | EP1506011A2 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| 02/16/2005 | EP1506010A2 Methylated immunostimulatory oligonucleotides and methods of using the same |
| 02/16/2005 | EP1506009A2 Glucan-based vaccines |
| 02/16/2005 | EP1506008A2 Mucosal vaccines with chitosan adjuvant and/or meningococcal antigens |
| 02/16/2005 | EP1506007A2 Mucosal combination vaccines for bacterial meningitis |
| 02/16/2005 | EP1506006A2 Improved combined vaccine against mycoplasma hyopneumoniae and porcine viruses |
| 02/16/2005 | EP1506005A1 Methods for the in vitro culture of sporozoea sp. and user thereof |
| 02/16/2005 | EP1506002A2 Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies |
| 02/16/2005 | EP1505981A2 Utilization of inhibitors of egfr-mediated signal transduction for the treatment of benign prostatic hyperplasia (bph)/prostatic hypertrophy |
| 02/16/2005 | EP1505942A2 Pathogen vaccines and methods for using the same |
| 02/16/2005 | EP1505873A2 Universal chimera bank |
| 02/16/2005 | EP1161548B1 Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein |
| 02/16/2005 | EP0846160B1 Methods for enhancing the production of viral vaccines in cell culture by interferon suppression |
| 02/16/2005 | EP0634896B1 Evaluation of patients with progressive immunosuppression |
| 02/16/2005 | CN1582337A 丙型肝炎病毒疫苗 Hepatitis C Virus Vaccine |
| 02/16/2005 | CN1582336A Moraxella (branhamella) catarrhalis antigens |
| 02/16/2005 | CN1582333A Live vaccine and method of manufacture |
| 02/16/2005 | CN1582301A Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 02/16/2005 | CN1582298A High-level composing production for anthrax protection antigen |
| 02/16/2005 | CN1582297A Hybrid and tandem expression of neisserial proteins |
| 02/16/2005 | CN1582178A Hematopoietic stem cell gene therapy |
| 02/16/2005 | CN1582165A Antibodies to CD40 |
| 02/16/2005 | CN1582164A Antigen arrays for treatment of bone disease |
| 02/16/2005 | CN1582156A Methods for treating ocular neovascular diseases |
| 02/16/2005 | CN1582149A Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels |
| 02/16/2005 | CN1580247A Esophagus carcinoma monoclonal antibody, and its radioactive marker and chemical cross-linked substance, and its use |
| 02/16/2005 | CN1580073A Human SARS virus surface film protein antigen determinant polypeptide, polynucleotide sequence and its use |
| 02/16/2005 | CN1580072A SARS coronary virus nail protein high-immune-protosegment, coding sequence and its use |
| 02/16/2005 | CN1579553A Method for preparing II-type pig's ring-virus nucleic vaccine and the use thereof |
| 02/16/2005 | CN1579550A Nucleic vaccine for tubercle bacillus |
| 02/16/2005 | CN1579548A Use of Hepatitis vaccine for preventing and treating series acute repiratory tract syndrome |
| 02/16/2005 | CN1579260A Biological agent for reducing specific nitrosamine content which tobacco has, preparation method and use |
| 02/16/2005 | CN1189557C Detecting and trapping receptor 3 monoclonal antibody, hybrid tumor for producing said antibody and its use |
| 02/16/2005 | CN1189484C Recombined human CD11a monclone antibody and its preparation and medicinal composition |
| 02/16/2005 | CN1189483C Humanized CD3-resisting monoclonal antibody |
| 02/16/2005 | CN1189213C Tolerance to xenograft |
| 02/16/2005 | CN1189210C Coupling object between CB and biological active peptide as well as medication usage thereof |
| 02/15/2005 | US6855812 P-glycoproteins and uses thereof |
| 02/15/2005 | US6855810 Ligands directed to the non-secretory component, non-stalk region of plgR and methods of use thereof |
| 02/15/2005 | US6855806 Comprises secreted polypeptide for diagnosis and treatment of tumors, nervous system, reproductive and muscular disorder |
| 02/15/2005 | US6855803 Protein having hemolytic activity and gene encoding the protein |
| 02/15/2005 | US6855802 Mutated peptide compounds, derived from hsp70, useful in cancer immunotherapy |
| 02/15/2005 | US6855686 Also administering to the subject an effective amount of an mda-7 protein. |
| 02/15/2005 | US6855535 Comprises serum-free culture; protease-free |
| 02/15/2005 | US6855528 Administering a covalently reactive antigen analog (CRAA) having an an epitope recognized irreversibly bound by catalytic antibody; autoimmune disease; a lymphoproliferative disorder; anticarcinogenic, -tumor, -inflammatory agents |
| 02/15/2005 | US6855520 Cell volume-regulated human kinase h-sgk |
| 02/15/2005 | US6855519 Methods for enhancing the production of interferon in cell culture |
| 02/15/2005 | US6855515 Preparing immune responsive polypeptide fragment with protein kinase c and/or nuclear mitotic apparatus protein activity for diagnosis and treatment of autoimmune diseases |
| 02/15/2005 | US6855492 Entrained antigen; oil in water emulsion; vaccine |
| 02/15/2005 | US6855331 Sustained release hydrophobic bioactive PLGA microspheres |
| 02/15/2005 | US6855323 Identification of the domain of Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) that mediates adhesion to chondroitin sulfate A |
| 02/15/2005 | US6855322 A highly purified protein, Plasmodium falciparum MSP-142, which retains folding and disulfide bridging of the native molecule and is useful as a diagnostic reagent, antibody production, and as a vaccine for malaria |
| 02/15/2005 | US6855321 Polyepitope carrier protein |
| 02/15/2005 | US6855320 Fusing to the antigen a non-hemolytic truncated form of listeriolysin O. |
| 02/15/2005 | US6855318 Multi-mer peptides derived from hepatitis C virus envelope proteins for diagnostic use and vaccination purposes |
| 02/15/2005 | US6855317 Immunological herpes simplex virus antigens and methods for use thereof |
| 02/15/2005 | US6855316 Combination of an adjuvant and an isolated p42 polypeptide comprising at least a portion of the 42 kDa C-terminal processing fragment of major merozoite surface protein gp195 from a Plasmodium falciparum isolate |
| 02/15/2005 | US6855315 Kits for detecting swine infertility and respiratory syndrome (SIRS) virus |
| 02/10/2005 | WO2005012910A1 A peptide antigen |
| 02/10/2005 | WO2005012538A2 Accelerated vaccination |
| 02/10/2005 | WO2005012537A2 Adenoviral vector-based vaccines |
| 02/10/2005 | WO2005012530A2 Antagonists and agonists of ldcam and methods of use |
| 02/10/2005 | WO2005012528A1 A method of preparing epitopes chimeric gene vaccine |
| 02/10/2005 | WO2005012494A2 Treatment of organ transplant rejection |
| 02/10/2005 | WO2005012493A2 Anti-cd19 antibodies |
| 02/10/2005 | WO2005012479A2 Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| 02/10/2005 | WO2005012407A2 Polymer encapsulation of adenoviruses |
| 02/10/2005 | WO2005012351A2 Novel functions for decay accelerating factor (daf) in inflammation |
| 02/10/2005 | WO2005012343A1 Babesia vaccines |
| 02/10/2005 | WO2005012339A2 Immunogenic protein and uses thereof |